Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRSW117 in Severe Hemophilia A
NCT06142552Phase 3Completed
- Sponsor
- Gensciences
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- PEGylated Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of pegylated recombinant human coagulation factor VIII-Fc fusion protein in hemophilia A, sponsored by Gensciences. Started Dec 2023; status: completed.
02
Drugs
pegylated recombinant human coagulation factor VIII-Fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06142552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06142552.